Group items tagged

This Funding Opportunity Announcement (FOA) supports the optimization of potential therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene and cell therapies) for disorders identified under the NINDS mission. This track supports the further characterization and optimization of therapeutic lead(s) that showed promise as a potential therapeutic agent as evidenced by convincing animal proof-of-concept studies. Therefore, at the end of this funding period, successful projects will have delivered and optimized therapeutic candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligible for entry into the CREATE Bio Development track. The CREATE Bio Development track is a later stage program focused on the development of optimized therapeutic candidates through Investigational New Drug (IND)-enabling studies and submission of an IND package to the Food and Drug Administration (FDA). This Funding Opportunity Announcement (FOA) supports the optimization of potential therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene and cell therapies) for disorders identified under the NINDS mission. This track supports the further characterization and optimization of therapeutic lead(s) that showed promise as a potential therapeutic agent as evidenced by convincing animal proof-of-concept studies. Therefore, at the end of this funding period, successful projects will have delivered and optimized therapeutic candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligible for entry into the CREATE Bio Development track. The CREATE Bio Development track is a later stage program focused on the development of optimized therapeutic candidates through Investigational New Drug (IND)-enabling studies and submission of an IND package to the Food and Drug Administration (FDA).

The Directorate for Biological Sciences (BIO) awards Postdoctoral Research Fellowships in Biology to recent recipients of the doctoral degree for research and training in selected areas supported by BIO and with special goals for human resource development in biology.  The fellowships encourage independence at an early stage of the research career to permit Fellows to pursue their research and training goals in the most appropriate research locations regardless of the availability of funding for the Fellows at that site.  For FY 2013, these BIO programs are (1) Broadening Participation in Biology; (2) Intersections of Biology and Mathematical and Physical Sciences and Engineering; (3) National Plant Genome Initiative Postdoctoral Research Fellowships; and (4) International Postdoctoral Research Fellowships in Biology.  These areas change periodically as new scientific and infrastructure opportunities present themselves. For this reason, this solicitation will be changed as necessary to reflect the areas being funded.

The US National Science Foundation (NSF) and the US-Israel Binational Science Foundation (BSF) have signed a Memorandum of Understanding (MOU) on Research Cooperation. The MOU provides an overarching framework to encourage collaboration between US and Israeli research communities and sets out the principles by which jointly supported activities might be developed. The MOU provides for an international collaboration arrangement whereby US researchers may receive funding from the NSF and Israeli researchers may receive funding from the BSF. The Division of Molecular and Cellular Biosciences (MCB) the Directorate for Biological Sciences (BIO) of the National Science Foundation and the US-Israel Binational Science Foundation are pleased to announce a US-Israel collaborative research opportunity. The goal is to help reduce some of the current barriers to working internationally. NSF/BIO/MCB and BSF will address these issues by allowing US and Israeli researchers to submit a single collaborative proposal that will undergo a single review process.

This Funding Opportunity Announcement (FOA) supports the optimization of potential therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene and cell therapies) for disorders identified under the NINDS mission. This track supports the further characterization and optimization of therapeutic lead(s) that showed promise as a potential therapeutic agent as evidenced by convincing animal proof-of-concept studies. Therefore, at the end of this funding period, successful projects will have delivered and optimized therapeutic candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligible for entry into the CREATE Bio Development track. The CREATE Bio Development track is a later stage program focused on the development of optimized therapeutic candidates through Investigational New Drug (IND)-enabling studies and submission of an IND package to the Food and Drug Administration (FDA).

The Directorate for Biological Sciences (BIO) awards Postdoctoral Research Fellowships in Biology (PRFB) to recent recipients of the doctoral degree for research and training in selected areas supported by BIO and with special goals for human resource development in biology. The fellowships encourage independence at an early stage of the research career to permit Fellows to pursue their research and training goals in the most appropriate research locations regardless of the availability of funding for the Fellows at that site. For applications under this solicitation, these areas are (1) Broadening Participation of Groups Underrepresented in Biology, (2) Interdisciplinary Research Using Biological Collections, (3) National Plant Genome Initiative (NPGI) Postdoctoral Research Fellowships and (4) Integrative Research Investigating the Rules of Life Governing Interactions Between Genomes, Environment and Phenotypes.

The Directorate for Biological Sciences (BIO) awards Postdoctoral Research Fellowships in Biology (PRFB) to recent recipients of the doctoral degree for research and training in selected areas supported by BIO and with special goals for human resource development in biology. The fellowships encourage independence at an early stage of the research career to permit Fellows to pursue their research and training goals in the most appropriate research locations regardless of the availability of funding for the Fellows at that site. For applications under this solicitation, these areas are (1) Broadening Participation of Groups Underrepresented in Biology, (2) Interdisciplinary Research Using Biological Collections, (3) National Plant Genome Initiative (NPGI) Postdoctoral Research Fellowships and (4) Integrative Research Investigating the Rules of Life Governing Interactions Between Genomes, Environment and Phenotypes.

Join BioOhio and the Columbus chapter of the Healthcare Businesswomen's Association (HBA) for a FREE online event - our second Diversity in Bioscience & Healthcare event of 2020, on August 20 at 5 pm. The engaging discussion focuses on the importance of supporting STEM programming at an early age within under-represented communities to encourage careers within the science and healthcare industries. Our special guests include: Frederic Bertley, Ph.D., President & CEO, COSI Kirsten M. Ellenbogen, Ph.D., President & CEO, Great Lakes Science Center Kelly Lewis, Bioscience Technologies Program Instructor, Eastland-Fairfield Career and Technical Schools Lead by the talented Brooke Cartus, Director of Business Development and Senior Facilitator, ImprovEdge! Featuring networking opportunities during the event! This discussion will be held via Zoom. Login instructions are included in your registration confirmation email and reminder emails sent before the event. BioOhio and the Healthcare Business Women's Association (HBA) support all efforts to increase diversity and inclusion within the bioscience and healthcare industries and invite you to join us for our next discussion, Overcoming Obstacles in the Workplace: Making Work Accessible on November 14th, 2020. This event is brought to you by BioOhio in partnership with the Columbus chapter of the Healthcare Businesswomen's Association (HBA) and is made possible by the generous support of BioOhio members AtriCure and BIO.

This Funding Opportunity Announcement (FOA) is dedicated to the discovery of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, and cell therapies) for disorders that fall under the NINDS mission.  It supports the optimization of therapeutic lead(s) showing convincing proof-of-concept.   At the end of the funding period, projects that successfully advance through support from this program will have identified a optimized candidate, which has sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, and will be ready for entry into the CREATE Bio Development track for further development to enable filing for an Investigational New Drug (IND).   

The Nano-Bio Manufacturing Consortium is expected to grow the US-centric innovation ecosystem that will risk reduce material supply (including nanomaterials & biomaterials), processing techniques, and flexible/stretchable device concepts by demonstrating component- and system-level functionality relevant to human-integrated technologies, such as airman-performance monitoring (APM) and augmentation (APA) systems. This public-private partnership should build upon the foundation of research & development excellence that has been established within NBMC since its 2013 inception. It is envisioned that technology development will require teaming between academia and industry in partnership with government researchers as well as with appropriate members of the regulatory and operational DoD communities. A balance between enabling component- and systems-level prototype development is expected to be realized through end-technologies between TRL 3 and TRL 6. It is expected that during the completion of certain NBMC projects, lab and/or field demonstrations will be conducted in partnership with relevant DoD partners to ensure that members of military human performance and/or aeromedical communities can assess the utility of developments and provide iterative feedback with respect to critical path issues.

This Funding Opportunity Announcement (FOA) supports SBIRs in the optimization of potential therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging modalities) for disorders identified under the NINDS mission. This track supports the further characterization and optimization of therapeutic agent(s) that showed promise as evidenced by relevant, rigorous, convincing in vivo studies. Therefore, at the end of this funding period, successful projects will have delivered an optimized therapeutic candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligible for entry into the CREATE Bio Development track.

This Funding Opportunity Announcement (FOA) supports the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging therapies) for disorders identified under the NINDS mission. An identified clinical candidate with sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required for entry to this CREATE Bio Development Track. Therefore, this FOA supports Investigational New Drug (IND)-enabling studies for a therapeutic candidate and the inclusion of an optional small delayed-onset first in human Phase I clinical trial. At the end of the funding period, a successful project should have at least an IND application submitted to the U.S. Food and Drug Administration (FDA).

The BioWatch Program is a cornerstone of the Department of Homeland Security's (DHS) comprehensive strategy for countering biological terrorism. The BioWatch Program is an early warning system that is designed to detect the intentional release of select aerosolized biological agents. The BioWatch Program's mission is to provide and maintain a continuous bio-terrorism air monitoring system in metropolitan areas and coordinate with state and local public health communities to prepare for and respond to a bioterrorist event. This mission is accomplished by serving as an early warning system which enhances the security of jurisdictions by providing the needed time to execute their comprehensive concept of operations plans to counter biological terrorism. The Biowatch Program is a critical part of an ongoing national effort to build and sustain preparedness which helps the United States to maintain momentum through targeted jurisdictional planning that highlights preventative actions necessary to allow for a proper and timely response and begin the process to recovery from a biological agent release.

It has been suggested that generic iron complex formulations could have higher levels of labile iron, leading to the formation of a greater amount of non-transferrin bound iron (NTBI) in vivo than the reference listed drug (RLD) that would potentiate oxidative stress and inflammation, then resulting in direct cellular damage. The objectives of this study are to evaluate various in-vitro methods of determining labile iron in the parenteral iron complex formulations and develop a bio-relevant in-vitro method to predict the amount of NTBI in vivo. Such a predictive in-vitro method will allow for linkage of FDA's equivalence standards to in vivo performance.

This Funding Opportunity Announcement (FOA) encourages exploratory and developmental grant applications to lay the foundation for innovative and collaborative basic research on the role of epigenetics in social, behavioral, environmental and biological relationships, throughout the life-span and across generations. Research plans that are responsive to this FOA will use existing bio-psycho-social and environmental data from human cohorts or animal studies that have biospecimens available for epigenetic profiling. The one year exploratory/developmental awards are expected to generate preliminary data for comprehensive basic research applications to study interactions between epigenetics and social/behavioral/biological/environmental factors in both normal function and pathophysiology throughout life and across generations. The results may ultimately inform research to develop clinical decision/diagnostic tools and prevention/treatment strategies.   

The objectives of the Molecular Signatures program are to identify and characterize critical molecular signatures relevant to Intelligence, Surveillance, and Reconnaissance (ISR) and Human Performance; to develop sensors for the detection of these signatures utilizing molecular, genomic, and nano-bio sensing elements; and to develop and employ data analysis tools for processing, exploitation, and dissemination of detected signatures for informed and efficient decision making.

As Synthetic Biology is the attempt to engineer biology, projects should incorporate engineering principles like modularity, abstraction, standardization and orthogonality and use modelling approaches to  optimize or improve a biological or bio-based unit. Unlike descriptive biological disciplines, projects are expected to use deliberate (re)design and construction of parts, devices or systems. Projects can  derive from basic research or more applied research areas in chemical biology, biophysics, biotechnology or biomedicine. Potential advances for society should be outlined in the proposal. 

The Instrument Development for Biological Research (IDBR) Program supports the development, production, and distribution of novel instrumentation that addresses demonstrated needs in biological research in areas supported by NSF Biology programs (see http://www.nsf.gov/bio). These systems would benefit a broad user community through mass distribution of the technology. Interdisciplinary collaborations are strongly encouraged, as are partnerships with U.S. industries that can facilitate knowledge transfer, commercialization and broad utilization in the research community. The program accepts two types of proposals:Type A - Innovation: Proposals for the development of novel instrumentation that provides new research capabilities or, where appropriate, that significantly improves current technologies by at least an order of magnitude in fundamental aspects such as accuracy, precision, resolution, throughput, flexibility, breadth of application, costs of construction or operation, or user-friendliness.Type B - Bridging: Proposals for transforming ‘one of a kind' prototypes or high-end instruments into devices that are broadly available and utilizable without loss of capacity. If appropriate, PIs should seek SBIR/STTR Program, or similar support mechanism for implementation of broad distribution following an IDBR award.

According to recent conversations between OARS staff and an NSF official, the NSF BioMaPS program is a funding opportunity that is perhaps undertargeted by researchers.  It funds interdisciplinary proposals that address "the interface between the biological, mathematical, and physical sciences and engineering."  Unsolicited proposals can be submitted to the deadlines of any relevant program in BIO, ENG, or MPS.  The label "BIOMAPS" should appear at the beginning of the proposal title.

An NSF official indicates that researchers in the BIO Directorate are well-served by being aware of the "Five Grand Challenges" in this report.

The National Institute on Drug Abuse (NIDA) supports a program of longitudinal cohorts to address emerging and high priority research on HIV/AIDS in the context of injection and non-injection substance abuse.  These cohorts provide a strong resource platform for current and future collaborative efforts with other investigators to address emerging questions related to HIV pathogenesis, prevention, and treatment in the context of substance abuse, as well as to foster the creativity and efficiency of investigator-initiated research projects. The diverse research activities among these cohorts include basic immunologic, and virologic studies, as well as studies on HIV prevention and treatment, and the co-morbidities and co-infections associated with HIV and substance abuse.  NIDA has determined that a coordinating center (CC) is needed in order to take advantage of these rich sources of data and bio-specimens and optimize collaborations among both the cohort investigators and other researchers not funded under the cohort program. In addition, the CC is expected to establish a virtual repository, and facilitate the leadership of the cohorts steering committee (SC), consisting of representatives from the NIDA-funded cohorts and NIDA staff. At this time, NIDA is soliciting  cooperative agreement applications for a CC to support the collaborative efforts of the cohorts that are currently funded by NIDA.